Evidence map›Paper›PMID 35222290›Full record

ReviewFrontiers in endocrinology2022

New Insights and Emerging Therapeutic Approaches in Prostate Cancer.

Fabrizio Licitra, Pia Giovannelli, Marzia Di Donato, Alessandra Monaco, Giovanni Galasso, Antimo Migliaccio, Gabriella Castoria

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Prostate Cancer and the Mevalonate Pathway.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Fabrizio LicitraDepartment of Precision Medicine, University of Campania 'L. Vanvitelli', Naples, Italy.
Pia GiovannelliDepartment of Precision Medicine, University of Campania 'L. Vanvitelli', Naples, Italy.
Marzia Di DonatoDepartment of Precision Medicine, University of Campania 'L. Vanvitelli', Naples, Italy.
Alessandra MonacoDepartment of Precision Medicine, University of Campania 'L. Vanvitelli', Naples, Italy.
Giovanni GalassoDepartment of Precision Medicine, University of Campania 'L. Vanvitelli', Naples, Italy.
Antimo MigliaccioDepartment of Precision Medicine, University of Campania 'L. Vanvitelli', Naples, Italy.
Gabriella CastoriaDepartment of Precision Medicine, University of Campania 'L. Vanvitelli', Naples, Italy.
University of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is the second most frequently diagnosed cancer in men and several therapeutic approaches are currently available for patient's care. Although the androgen receptor status represents a good predictor of response to androgen deprivation therapy, prostate cancer frequently becomes resistant to this approach and spreads. The molecular mechanisms that contribute to progression and drug-resistance of this cancer remain still debated. However, few therapeutic options are available for patient's management, at this stage. Recent years have seen a great expansion of the studies concerning the role of stromal-epithelial interactions and tumor microenvironment in prostate cancer progression. The findings so far collected have provided new insights into diagnostic and clinical management of prostate cancer patients. Further, new fascinating aspects concerning the intersection of the androgen receptor with survival factors as well as calcium channels have been reported in cultured prostate cancer cells and mouse models. The results of these researches have opened the way for a better understanding of the basic mechanisms involved in prostate cancer invasion and drug-resistance. They have also significantly expanded the list of new biomarkers and druggable targets in prostate cancer. The primary aim of this manuscript is to provide an update of these issues, together with their translational aspects. Exploiting the power of novel promising therapeutics would increase the success rate in the diagnostic path and clinical management of patients with advanced disease.

Indexed as

Androgen AntagonistsProstatic NeoplasmsAnimalsHumansMaleMiceProstateTumor MicroenvironmentAndrogen Antagonistscalcium influxcancer-associated fibroblastsnerve growth factor signallingnew drugsprostate cancer

Identifiers

PMID35222290
PMCPMC8873523
OpenAlexW4211030993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.